Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis

Exclusion Criteria

• •Diagnosis of Felty's syndrome, psoriatic arthritis, gout, or auto-immune rheumatic disease
• •Any surgical procedure within 30 days of Screening or likely to need joint or tendon surgery or other surgical procedure during the study
• •Intra-articular or intra-muscular corticosteroids within 60 days prior to dosing
• •Previous treatment with any biologic response modifying agent for RA within 90 days or 5 half-lives, whichever is greater, prior to screening
• •Previous treatment with rituximab at any time
• •Use of corticosteroid therapy equivalent to an average daily dose of \>10 mg of prednisone
• •Any Screening laboratory values that are out of allowed reference ranges
• •Inability to comply with protocol or study procedures
• •Any other significant illness or condition that may adversely affect the subjects participation in the study